How strong is the evidence that vaccination prevents cancer, not just CIN?

The evidence that HPV vaccination prevents cancer (not just CIN) is moderate for cervical cancer, weak for other HPV-related cancers, and relies on observational studies, not randomized trials with cancer as the endpoint.

The strongest evidence comes from a large English population study. Among women offered routine HPV vaccination at age 12-13, invasive cervical cancer incidence was 83.9% lower than in unvaccinated cohorts by mid-2020 [3]. The same study estimated 687 cervical cancers were prevented across all vaccinated cohorts [3]. This is a real cancer outcome, not a surrogate.

But the English study is observational, not a randomized trial. It compares birth cohorts offered vaccination to older cohorts who were not. This design cannot fully separate the vaccine's effect from changes in screening, sexual behavior, or other factors over time. The original clinical trials for the quadrivalent vaccine reported 95% efficacy against CIN2/3 in HPV-naive women, but only 36% efficacy in the general population [5]. Those trials measured precancer, not cancer.

For non-cervical cancers, the evidence is thinner. A 2026 systematic review found that HPV vaccination was associated with lower oral vaccine-type HPV prevalence (about 78% relative reduction), but a longitudinal cohort found no significant reduction in incident oral HPV infection (adjusted hazard ratio 1.22, 95% CI 0.87-1.71) [4]. No study in this retrieval directly measured prevention of oropharyngeal, anal, or penile cancers.

Meanwhile, cervical cancer rates are rising in some vaccinated populations. A 2025 Canadian study found that rates in women aged 35-44 increased from 12.7 to 18.1 per 100,000 between 2001 and 2022, despite HPV vaccination and screening [1]. A 2026 U.S. study found that while overall cervical cancer incidence declined, the proportion of stage IV diagnoses increased from 10.1% to 15.5% [2]. These trends complicate the claim that vaccination alone is driving cancer prevention.

My call: the HPV vaccine likely reduces cervical cancer risk, but the evidence is observational, not from randomized cancer trials, and rising cancer rates in some age groups suggest other factors matter. Confidence: moderate for cervical cancer, low for other cancers.